TOP TEN perturbations for 38424_at (Homo sapiens)

Organism: Homo sapiens
Gene: 38424_at
Selected probe(set): 208858_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 38424_at (208858_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

PMA; ionomycine study 2 / unstimulated CD4 memory T-cell sample

Relative Expression (log2-ratio):-2.930581
Number of Samples:8 / 8
Experimental PMA; ionomycine study 2
CD4+ memory T cells derived from peripheral blood of healthy subjects were stimulated for 3 hours with phorbol 12-myristate 13-acetate (PMA, 10 ng/ml) and ionomycin (1 µg/ml). ATC code:---
Control unstimulated CD4 memory T-cell sample
Unstimulated CD4+ memory T cells derived from peripheral blood of healthy subjects.

HCT 116 DICER1(-/-) / p53HCT116

Relative Expression (log2-ratio):2.7282915
Number of Samples:3 / 3
Experimental HCT 116 DICER1(-/-)
Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout DICER gene in exon 5 by using an AAV targeting construct. Parental cell line:: HCT 116 Synonyms:DICER1 (-/-) HCT116; HCT116 DICEREX5/EX5, DICERex5 Cellosaurus code:
Control p53HCT116
Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout gene for p53. Parental cell line:: HCT 116 Synonyms:P53HCT116; p53-/- HCT116; p53(-/-) HCT-116; HCT116-p53-/-; HCT116-p53 Cellosaurus code:

phenobarbital study 3 (10000uM) / vehicle (medium) treated hepatocyte sample

Relative Expression (log2-ratio):-2.72748
Number of Samples:2 / 2
Experimental phenobarbital study 3 (10000uM)
Hepatocytes treated with compound: phenobarbital (10000uM; CHEMBL40) for 24 hours. ATC code:
Control vehicle (medium) treated hepatocyte sample
Hepatocytes treated with vehicle (medium) for 24 hours.

oncolytic herpes simplex virus study 2 / mock infected peripheral nerve sheath tumor (S462) cell sample

Relative Expression (log2-ratio):-2.6980782
Number of Samples:3 / 3
Experimental oncolytic herpes simplex virus study 2
Human malignant peripheral nerve sheath tumor (S462) cells infected with G207, an ICP34.5-deleted oncolytic herpes simplex virus (oHSV) for 6 hours.
Control mock infected peripheral nerve sheath tumor (S462) cell sample
Human malignant peripheral nerve sheath tumor (S462) cells mock infected for 6 hours.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample

Relative Expression (log2-ratio):2.6238098
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal B-cell sample
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

p53HCT116 / HCT 116

Relative Expression (log2-ratio):-2.5622149
Number of Samples:3 / 3
Experimental p53HCT116
Human primary cancer cell line derived from the colon of a patient with carcinoma. The cells have knockout gene for p53. Parental cell line:: HCT 116 Synonyms:P53HCT116; p53-/- HCT116; p53(-/-) HCT-116; HCT116-p53-/-; HCT116-p53 Cellosaurus code:
Control HCT 116
Human primary cancer cell line derived from the colon of a patient with carcinoma. Synonyms:HCT-116; HCT.116; HCT116 Cellosaurus code:

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):2.4072962
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

T-cell isolation study 11 / T-cell isolation study 6

Relative Expression (log2-ratio):-2.1958456
Number of Samples:2 / 2
Experimental T-cell isolation study 11
CD4+ resting memory T-cell were isolated from peripheral blood buffy coat of healthy donors after storage for 24 hours at 20°C. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.
Control T-cell isolation study 6
CD4+ resting memory T-cell were isolated from whole peripheral blood of healthy donors with no delay. The cell fraction was first enriched via density gradient centrifugation with LSM 1077 Ficoll and than FACS sorted as CD3+/CD4+/CD45RO+/CD45RA- population.

septic shock study 3 (D1; survivor) / normal blood sample

Relative Expression (log2-ratio):-2.1572456
Number of Samples:34 / 22
Experimental septic shock study 3 (D1; survivor)
Blood samples from patients (survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D1; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-2.1406755
Number of Samples:17 / 22
Experimental septic shock study 3 (D1; non-survivor)
Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.